In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion

Drug Development and Industrial Pharmacy

Volumn 36, Issue 6, 2010, Pages 681-687

  He, Haibing ^a   Yang, Rui ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Dissolution test; Fenofibrate; Hot melt extrusion; Solid dispersion

Indexed keywords

EUDRAGIT; FENOFIBRATE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DOG; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; THERMOGRAVIMETRY; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOGS; DRUG EVALUATION, PRECLINICAL; FENOFIBRATE; HOT TEMPERATURE; X-RAY DIFFRACTION;

EID: 77952503676     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903449720     Document Type: Article

References (26)

1. Nearing GM, Ormrod D. (2002). Micronised fenofibrate: An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 62:1909-44.
2. Guay DR. (2002). Update on fenofibrate. Cardiovasc Drug Rev 20:281-302.
3. Ramjattan BR, Callaghan DJ, Theiss U. (2002). Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: A pooled analysis of two open-label trials. Clin Ther 24:1105-16.
4. Sheu MT, Yeh CM, Sokoloski TD. (1994). Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm 103:137-46.
5. Palmeiri GF, Antonini I, Martelli S. (1996). Characterization and dissolution studies of PEG4000/fenofibrate solid dispersions. STP. Pharm Sci 6:188-94.
6. Munoz A, Guichard JP, Reginault E. (1994). Micronised fenofibrate. Atherosclerosis 110 (Suppl.):S45-8.
7. Pol-Henri G, Michael GV, Diana F. (2004). A new fenofibrate formulation: Results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clin Ther 26:1456-69.
8. Hülsmann S, Backensfeld T, Keitel S, Bodmeier R. (2000). Melt extrusion-an alternative method for enhancing the dissolution rate of 17ß-estradiol hemihydrate. Eur J Pharm Biopharm 49:237-42.
9. Nakamichi K, Nakano T, Yasuura H. (2002). The role of the kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin-screw extruder. Int J Pharm 241:203-11.
10. Perissutti B, Newton JM, Podczeck F, Rubessa F. (2002). Preparation of extruded carbamazepine and PEG4000 as a potential rapid release dosage form. Eur J Pharm Biopharm, 53:125-32.
11. Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J, et al. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, part II. Pharm Res, 20:1047-54. (Pubitemid 36774276)
12. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusionpart I. Int J Pharm, 251:165-74. (Pubitemid 36071471)
13. Crowley MM, Schroeder B, Fredersdorf A, Obara S, Talarico M, Kucera S, et al. (2004). Physicochemical properties and mechanism of drug release from ethyl cellulose matrix tablets prepared by direct compression and hot-melt extrusion. Int J Pharm, 269:509-22.
14. De Brabander C, Vervaet C, Remon JP. (2003). Development and evaluation of sustained release mini-matrices prepared via hot melt extrusion. J Control Release, 89:235-47.
15. Follonier N, Doelker E, Cole ET. (1994). Evaluation of hot-melt extrusion as a new technique for the production of polymerbased pellets for sustained-release capsules containing high loading of freely water soluble drugs. Drug Dev Ind Pharm, 20:1323-39.
16. Fukuda M, Peppas NA, McGinity JW. (2006). Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. Int J Pharm, 310:90-100.
17. Liu J, Zhang F, McGinity JW. (2001). Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion. Eur J Pharm Biopharm, 52:181-90.
18. ® core for sustained drug delivery. J Control Release, 94:273-80.
19. Mehuys E, Remon JP, Vervaet C. (2005). Production of enteric capsules by means of hot-melt extrusion. Eur J Pharm Sci, 24:207-12.
20. Nakamichi K, Yasuura H, Fukui H, Oka M, Izumi S. (2001). Evaluation of a floating dosage form of nicerdipine hydrochloricde and hydroxylpropylmethylcellulose acetate succinate prepared using a twin-screw extruder. Int J Pharm, 218:103-12.
21. Crowley MM, Fredersdorf A, Schroeder B, Kucera S, Prodduturi S, Repka MA, et al. (2004). The influence of guaifenesin and ketoprofen on the properties of hot-melt extruded polyethylene oxide films. Eur J Pharm Sci, 22:409-18.
22. Prodduturi S, Manek RV, Kolling W M, Stodghill SP, Repka MA. (2004). Water vapor sorption of hot-melt extruded hydroxypropyl cellulose films: Effect on physico-mechanical properties, release characteristics, and stability. J Pharm Sci, 93:3047-56.
23. Prodduturi S, Manek RV, Kolling WM, Stodghill SP, Repka MA. (2005). Solid-state stability and characterization of hot-melt extruded poly (ethylene oxide) films. J Pharm Sci, 94:2232-45.
24. Repka MA, McGinity JW. (2001). Bioadhesive properties of hydroxypropylcellulose topical films produced by hot-melt extrusion. J Control Release, 70:341-51.
25. Repka MA, Gutta K, Prodduturi S, Munjal M, Stodghill SP. (2005). Characterization of cellulosic hot-melt extruded films containing lidocaine. Eur J Pharm Biopharm, 59:189-96. (Pubitemid 39573452)
26. Greenhalgh DJ, Williams AC, Timmins P, York P. (1999). Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci, 88:1182-90.